4/12
08:14 am
rvnc
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]
4/12
08:03 am
rvnc
Revance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the company [Yahoo! Finance]
Low
Report
Revance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the company [Yahoo! Finance]
4/12
08:00 am
rvnc
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Medium
Report
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
3/27
04:21 pm
rvnc
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/27
04:05 pm
rvnc
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/12
08:37 am
rvnc
Spirair, Developer of the First and Only Minimally Invasive Therapy for Mechanical Correction of Nasal Septal Deviation, Announces Appointment of Benjamin Bishop as Chief Executive Officer [Yahoo! Finance]
Low
Report
Spirair, Developer of the First and Only Minimally Invasive Therapy for Mechanical Correction of Nasal Septal Deviation, Announces Appointment of Benjamin Bishop as Chief Executive Officer [Yahoo! Finance]
3/11
12:17 pm
rvnc
Global Cell Penetrating Peptide Market to Reach $8.40 Billion by 2030 Owing To Increasing Demand for Targeted Drug Delivery Systems | Says Coherent Market Insights [Yahoo! Finance]
Low
Report
Global Cell Penetrating Peptide Market to Reach $8.40 Billion by 2030 Owing To Increasing Demand for Targeted Drug Delivery Systems | Says Coherent Market Insights [Yahoo! Finance]
3/4
09:25 am
rvnc
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Medium
Report
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
3/4
07:45 am
rvnc
Revance Therapeutics down 7%, prices $100M share offering [Seeking Alpha]
Medium
Report
Revance Therapeutics down 7%, prices $100M share offering [Seeking Alpha]
3/4
06:51 am
rvnc
Revance Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Revance Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
3/4
06:37 am
rvnc
Revance Announces Proposed Public Offering of Common Stock
Medium
Report
Revance Announces Proposed Public Offering of Common Stock
3/2
08:33 am
rvnc
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
High
Report
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/2
08:07 am
rvnc
US$16.33: That's What Analysts Think Revance Therapeutics, Inc. (NASDAQ:RVNC) Is Worth After Its Latest Results [Yahoo! Finance]
High
Report
US$16.33: That's What Analysts Think Revance Therapeutics, Inc. (NASDAQ:RVNC) Is Worth After Its Latest Results [Yahoo! Finance]
3/1
08:14 am
rvnc
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $8.00 to $9.00. They now have a "neutral" rating on the stock.
Medium
Report
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $8.00 to $9.00. They now have a "neutral" rating on the stock.
3/1
06:02 am
rvnc
Revance Therapeutics Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Revance Therapeutics Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
2/29
05:36 pm
rvnc
Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain [Seeking Alpha]
Low
Report
Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain [Seeking Alpha]
2/29
03:42 pm
rvnc
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
2/29
09:10 am
rvnc
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $18.00. They now have a "buy" rating on the stock.
High
Report
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $18.00. They now have a "buy" rating on the stock.
2/29
09:10 am
rvnc
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at Piper Sandler from $42.00 to $20.00. They now have an "overweight" rating on the stock.
High
Report
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at Piper Sandler from $42.00 to $20.00. They now have an "overweight" rating on the stock.
2/28
04:53 pm
rvnc
Revance Therapeutics Inc (RVNC) Reports Strong Revenue Growth in Q4 and Full Year 2023 [Yahoo! Finance]
High
Report
Revance Therapeutics Inc (RVNC) Reports Strong Revenue Growth in Q4 and Full Year 2023 [Yahoo! Finance]
2/28
04:13 pm
rvnc
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update [Yahoo! Finance]
High
Report
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update [Yahoo! Finance]
2/28
04:05 pm
rvnc
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
High
Report
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
2/23
10:12 am
rvnc
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.
2/21
08:24 am
rvnc
Revance to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Revance to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/21
08:01 am
rvnc
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
Low
Report
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024